NEW YORK – Zymo Research has filed an amended response and counterclaims in a lawsuit brought against it by Qiagen in August for allegedly infringing patents related to nucleic acid sample preparation.

纽约——Zymo Research在Qiagen于8月份对其提起的诉讼中提出了修改后的回应和反诉，指控其侵犯了与核酸样品制备有关的专利。

In a late October filing with the US District Court for the Central District of California, Zymo denied all allegations in Qiagen's lawsuit, which claims that Zymo's MagicBead cfDNA Isolation Kit infringes on Qiagen's US Patent Nos. 10,184,145 and 11,021,736, which cover magnetic bead-based sample preparation of extracellular nucleic acids from cell-free or cell-depleted samples and are used in Qiagen's QiaSymphony PAXgene Blood ccfDNA Kit and QiaAmp MinElute ccfDNA Kit..

在10月底向美国加州中区地方法院提交的一份文件中，Zymo否认了Qiagen诉讼中的所有指控，该诉讼声称Zymo的MagicBead cfDNA分离试剂盒侵犯了Qiagen的美国专利号10184145和11021736，该专利涵盖了从无细胞或细胞耗尽的样品中制备细胞外核酸的磁珠样品，并用于Qiagen的QiaSymphony PAXgene血液ccfDNA试剂盒和QiaAmp MinElute ccfDNA试剂盒。。

Furthermore, Zymo asserted in its response that the claims in the '145 and '736 patents are invalid under the obviousness doctrine, that the patents are unenforceable under the doctrine of patent misuse, and that the lawsuit is frivolous in nature.

此外，Zymo在其回复中声称，根据显而易见原则，145年和736年专利中的权利要求无效，根据专利滥用原则，这些专利不可执行，并且该诉讼本质上是微不足道的。

In addition, Zymo claimed that Qiagen has misused its patents by seeking to broaden their scope and knowingly and willingly engaged in other activities to 'obtain or maintain anticompetitive power improperly in the US.' Moreover, Zymo claimed that Qiagen's anticompetitive conduct has injured its business both directly and through intentional interference with business relationships between Zymo and third parties..

此外，Zymo声称，Qiagen滥用其专利，试图扩大其范围，并故意和自愿从事其他活动，以“在美国不正当地获得或维持反竞争权力”。此外，Zymo声称，Qiagen的反竞争行为直接或通过故意干扰Zymo与第三方之间的业务关系，损害了其业务。。

In its demand for a jury trial, Zymo said it is seeking judgment of noninfringement of the Qiagen patents and/or declaration that the asserted patents are invalid and unenforceable. It is also seeking punitive damages and attorneys' fees.

Zymo在要求陪审团审判时表示，它正在寻求对Qiagen专利不侵权的判决和/或声明声称的专利无效且不可执行。它还寻求惩罚性赔偿和律师费。

'Qiagen's lawsuit was not brought in good faith and lacks merit,' Marc Van Eden, VP of corporate development for Irvine, California-based Zymo, said in a statement. 'The scientific community deserves access to cutting-edge tools that foster growth and discovery, and we are committed to defending our breakthrough [cell-free] DNA technology and our contributions to the scientific community.'.

总部位于加利福尼亚州欧文市的Zymo公司发展副总裁马克·范·伊登（MarcvanEden）在一份声明中说，Qiagen的诉讼并非出于善意，也缺乏依据科学界理应获得促进增长和发现的尖端工具，我们致力于捍卫我们的突破性[无细胞]DNA技术以及我们对科学界的贡献。”。